BURLINGTON, Mass. (May 14, 2015) - inVentiv Health, a global provider of best-in-class clinical development and comprehensive commercialization services, announced today that seven outstanding female leaders from across the company were honored for their dedication to the healthcare industry by the Healthcare Businesswomen’s Association (HBA).
HBA recognizes women each year who exhibit visionary leadership skills, are solely dedicated to the healthcare industry and contribute significantly to their organizations. Two forms of recognition exist, including “Rising Stars,” which honors women at various stages in their careers who exemplify leadership and top talent and “Luminaries,” which honors those who have enjoyed rapid career advancement since receiving earlier recognition as “Rising Stars.”
“We are proud of our colleagues and delighted by the recognition they have received,” said Michael Bell, Chairman and CEO of inVentiv Health. “Their work, and the work they inspire from their colleagues, contributes to inVentiv Health’s leadership in both drug development and commercialization. The dedication of these women accelerates their clients’ success to deliver innovative treatments to patients worldwide.”
The experience of these seven inVentiv Health women spans a variety of disciplines, including clinical development, advertising, public relations and consulting. The honorees include:
- Amy Hutnik, Executive Vice President of Strategy and Operations within inVentiv Health’s Commercial Division, leads a 19-person team within Program Management, leveraging her prior experience in agency operations and best practice implementation.
- Amanda Joly, Senior Vice President Head of Operations and Strategy at GSW, engages diverse audiences across various therapeutic categories. She played an integral role in applying GSW’s branding initiative, Speak People, to the agency's strategic offering.
- Rachel Stahler, Chief Information Officer in inVentiv Health’s Clinical Division, specializes in integrating complex IT systems into clinical trials, bringing new medicines to market.
- Danielle DeForge, Director of Corporate Communications for inVentiv Health, executes impactful communications activities for the company. She played a critical role in launching inVentiv Health’s global intranet, inFuse, which won PRNews’ Intranet of the Year award in 2014.
- Lynn Forrest, Vice President at Campbell Alliance, is the go-to authority on new product strategy, commercial excellence and market access for company clients and colleagues.
- Liz Frank, Senior Team Leader and Strategist at Biosector 2, provides public relations clients with top-tier medical communications based on nearly 20 years of experience working in CNS disorders, cardiology, respiratory, women’s health and anti-infectives.
- Jillian Welker, Director of Agency Operations at PALIO, works closely with cross-functional leadership to oversee process implementation, strategic excellence, creative innovation and client satisfaction. With more than 10 years of project management and account services experience, Jillian’s expertise leverages both online and offline marketing to implement innovative solutions for PALIO’s clients.
“It’s thanks to these women, and other talented professionals working across inVentiv Health, that we are able to help clients improve performance, reduce risk and speed much-needed therapies to market,” Bell said. “We congratulate them on this honor.”
About inVentiv Health inVentiv Health is a global provider of best-in-class clinical development and comprehensive commercialization services, seamlessly linking the capabilities of a leading, global Clinical Research Organization (CRO) with a unique Contract Commercial Organization (CCO). inVentiv Health helps clients improve performance, reduce risk and speed much-needed therapies to market. With 13,000 employees providing services to clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies developing and delivering medicines in a complex operating, regulatory and reimbursement environment. Our clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team.
inVentiv Health brings business strategy to science and scientific expertise to business for the better treatment of patients worldwide. For more information, visit www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our debt instruments and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.